Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer

Virchows Archiv

Volumn 467, Issue 6, 2015, Pages 667-673

  Roh, Mee Sook ^a   Lee, Ji Hyun ^b   Kang, Kyung Woo ^b   Nam, Hyun Yeol ^b   Jung, Sang Bong ^c   Kim, Kyungeun ^d   Lee, Eun Hee ^b   Park, Moon il ^b   Kim, Mee Seon ^b   Lee, Hyoun Wook ^b  

^a Dong A University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Dong eui Institute of Technology   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Immunohistochemistry; p 4E BP1; Prognosis; Small cell lung cancer

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; SMOKING; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 84949532433     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1860-2     Document Type: Article

References (25)

1. Amini A, Byers LA, Welsh JW, Komaki RU (2014) Progress in the management of limited-stage small cell lung cancer. Cancer 120:790–798
2. Argiris A, Murren JR (2001) Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7:437–447
3. Kalemkerian GP (2014) Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 15:2385–2396
4. Rossi G, Bisagni A, Cavazza A (2014) High-grade neuroendocrine carcinoma. Curr Opin Pulm Med 20:332–339
5. Armengol G, Rojo F, Castellví J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramón y Cajal S (2007) 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 67:7551–7555
6. Averous J, Proud CG (2006) When translation meets transformation: the mTOR story. Oncogene 25:6423–6435
7. Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY, Tseng CK, Chang HK, Hsueh C (2011) High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 458:171–178
8. Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA (2012) Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 61:293–305
9. Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, Ramon Y, Cajal S (2009) Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol 40:1418–1426
10. O’Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I (2009) Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15:2872–2878
11. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801–1811
12. Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P (2013) A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 30:623–636
13. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17:977–987
14. Ou SH, Ziogas A, Zell JA (2009) Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43
15. Sun JM, Choi YL, Ji JH, Ahn JS, Kim KM, Han J, Ahn MJ, Park K (2015) Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol 26:161–166
16. Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, Yoo K, Song JS (2000) Characteristics of lung cancer in Korea, 1997. Lung Cancer 30:15–22
17. Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, Park K, Ou SH (2010) Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 5:1185–1196
18. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW (2007) Lung cancer incidence in never smokers. J Clin Oncol 25:472–478
19. Lemaître V, Dabo AJ, D’Armiento J (2011) Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling. Toxicol Sci 123:542–549
20. Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M, Zhang L, Gandjeva A, Zhen L, Chukwueke U, Mao T, Richter A, Brown E, Ashush H, Notkin N, Gelfand A, Thimmulappa RK, Rangasamy T, Sussan T, Cosgrove G, Mouded M, Shapiro SD, Petrache I, Biswal S, Feinstein E, Tuder RM (2010) Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat Med 16:767–773
21. Memmott RM, Dennis PA (2010) The role of the Akt/mTOR pathway in tobacco-carcinogen induced lung tumorigenesis. Clin Cancer Res 16:4–10
22. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH, Eastern Cooperative Oncology Group (E1500) (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2:1036–1041
23. Zhang Y, He J (2013) The development of targeted therapy in small cell lung cancer. J Thorac Dis 5:538–548
24. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi99–v105
25. Nishi T, Iwasaki K, Ohashi N, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kobayashi T, Kodera Y (2013) Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Lett 331:220–229